IMPLANET: Implanet Reports an Improvement in Its 2020 Results
Gross margin improvement to 58.2%, versus 56% in 2019
Strengthened cash position
Regulatory Nws:
IMPLANET (Paris:ALIMP) (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral and knee-surgery implants, announces its results for the financial year to December 31, 2020, approved by the Board of Directors on February 16, 2021.
Within the very unique public health context that affected 2020, we generated over 6 million euros in revenue and continued to improve the gross margin ,
commented Implanet CEO Ludovic Lastennet.
These results strengthen our confidence in our resiliency during a period during which surgical programs have been heavily disrupted by postponements or cancellations. Our external growth strategy, notably through the acquisition project announced in January, indicates our intention of creating synergies in order
Implanet Announces 2020 Revenue of €6 Million
Fourth quarter JAZZ sales up 9% compared with the fourth quarter of 2019, with 34% growth in the United States
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans) (Paris:ALIMP), a medical technology company specializing in vertebral and knee-surgery implants, today announced its provisional unaudited fourth-quarter revenue, annual revenue and cash position at December 31, 2020.
Ludovic Lastennet, Implanet s Chief Executive Officer, commented:
Although down versus prior year, our revenue totaled €6 million in 2020, illustrating our ability to remain resilient in a period heavily impacted by the public health crisis and the cancellation or postponement of surgical operations. In the fourth quarter, the decrease in Knee activity in France was partly offset by significant growth in JAZZ